Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $7.80

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $7.80.

Several equities research analysts recently commented on the stock. Needham & Company LLC reissued a "buy" rating and set a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Morgan Stanley restated an "overweight" rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th.

TScan Therapeutics Trading Down 1.6%

Shares of TCRX stock traded down $0.03 during mid-day trading on Wednesday, reaching $1.81. The stock had a trading volume of 228,621 shares, compared to its average volume of 410,692. The stock's 50-day moving average price is $1.50 and its two-hundred day moving average price is $1.83. TScan Therapeutics has a 52-week low of $1.02 and a 52-week high of $7.89. The firm has a market capitalization of $102.43 million, a PE ratio of -1.66 and a beta of 0.97. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.15.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. Equities analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp bought 1,388,794 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $1.20 per share, for a total transaction of $1,666,552.80. Following the completion of the transaction, the insider owned 6,746,141 shares in the company, valued at $8,095,369.20. The trade was a 25.92% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.35% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Tocqueville Asset Management L.P. increased its stake in TScan Therapeutics by 26.8% in the 4th quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company's stock worth $793,000 after buying an additional 55,140 shares during the period. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics in the 4th quarter valued at about $32,000. JPMorgan Chase & Co. boosted its stake in TScan Therapeutics by 109.9% in the 4th quarter. JPMorgan Chase & Co. now owns 66,756 shares of the company's stock worth $203,000 after purchasing an additional 34,951 shares in the last quarter. Wellington Management Group LLP boosted its stake in TScan Therapeutics by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock worth $404,000 after purchasing an additional 6,550 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.